- Home
- CHCT vs SAGE Comparison
CHCT vs SAGE Comparison
Compare CHCT & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHCT
- SAGE
- Stock Information
- Founded
- CHCT 2014
- SAGE 2010
- Country
- CHCT United States
- SAGE United States
- Employees
- CHCT N/A
- SAGE N/A
- Industry
- CHCT Real Estate Investment Trusts
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- CHCT Real Estate
- SAGE Health Care
- Exchange
- CHCT Nasdaq
- SAGE Nasdaq
- Market Cap
- CHCT 551.0M
- SAGE 444.1M
- IPO Year
- CHCT 2015
- SAGE 2014
- Fundamental
- Price
- CHCT $18.79
- SAGE $7.31
- Analyst Decision
- CHCT Buy
- SAGE Hold
- Analyst Count
- CHCT 4
- SAGE 20
- Target Price
- CHCT $21.25
- SAGE $10.67
- AVG Volume (30 Days)
- CHCT 216.8K
- SAGE 1.8M
- Earning Date
- CHCT 02-18-2025
- SAGE 02-11-2025
- Dividend Yield
- CHCT 9.88%
- SAGE N/A
- EPS Growth
- CHCT N/A
- SAGE N/A
- EPS
- CHCT N/A
- SAGE N/A
- Revenue
- CHCT $115,786,000.00
- SAGE $41,243,000.00
- Revenue This Year
- CHCT N/A
- SAGE $123.13
- Revenue Next Year
- CHCT $7.55
- SAGE $69.65
- P/E Ratio
- CHCT N/A
- SAGE N/A
- Revenue Growth
- CHCT 2.61
- SAGE N/A
- 52 Week Low
- CHCT $15.06
- SAGE $4.62
- 52 Week High
- CHCT $27.73
- SAGE $23.22
- Technical
- Relative Strength Index (RSI)
- CHCT 39.29
- SAGE 60.55
- Support Level
- CHCT $18.36
- SAGE $7.00
- Resistance Level
- CHCT $20.28
- SAGE $7.26
- Average True Range (ATR)
- CHCT 0.52
- SAGE 0.19
- MACD
- CHCT -0.19
- SAGE -0.06
- Stochastic Oscillator
- CHCT 22.40
- SAGE 57.14
About CHCT Community Healthcare Trust Incorporated
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems or other healthcare service providers in non-urban markets. The company derives majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.